Diagnosis and management of hereditary haemochromatosis

BMJ

Volumn 342, Issue 7790, 2011, Pages 218-223

  Van Bokhoven, M A ^a   Van Deursen, C Th B M ^b   Swinkels, D W ^c  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b Sittard Geleen Heerlen   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL FEATURE; EARLY DIAGNOSIS; GENE MUTATION; GENETIC RISK; HEMOCHROMATOSIS; HUMAN; PATHOPHYSIOLOGY; PENETRANCE; PRIORITY JOURNAL; REVIEW;

BIOPSY; CYTAPHERESIS; DIAGNOSIS, DIFFERENTIAL; EARLY DIAGNOSIS; GENETIC TECHNIQUES; HEMOCHROMATOSIS; HUMANS; IRON CHELATING AGENTS; LIVER; MAGNETIC RESONANCE IMAGING; MUTATION; PHLEBOTOMY; PROGNOSIS; TRANSFERRIN;

EID: 78751695016     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.c7251     Document Type: Review

References (39)

1. European Association for the Study of the Liver. EASL clinical practice guidelines for HFE hemochromatosis. J Hepatol 2010;53:3-22.
2. Cuijpers M, Raymakers R, MacKenzie A, de WitteT, Swinkels D. Recent advances in the understanding of iron overload in sideroblastic myelodysplastic syndrome. Br J Haematol 2010;149:322-3.
3. Lee PL, Beutler E. Regulation of hepcidin and iron-overload disease. Annu Rev Pathol Mech Dis 2009;4:489-515.
4. Whitlock E, Garlitz B, Harris E, Beil T, Smith P. Screening for hereditary hemochromatosis: a systematic review for the US Preventive Services Task Force.Ann Intern Med 2006;145:209-23. (Pubitemid 46780566)
5. Beutler E, Felitti VJ, Koziol JA, Ho NJ, Gelbart T. Penetrance of 845G→A (C282Y) HFE hereditary haemochromatosis mutation in the USA. Lancet 2002;359:211-8. (Pubitemid 34113819)
6. Allen KJ, Gurrin LC, Constantine CC, Osborne NJ, Delatycki MB, Nicoll AJ, et al. Iron-overload-related disease in HFE hereditary hemochromatosis. N Engl J Med 2008;358:221-30.
7. Wood MJ, Powell LW, Ramm GA. Environmental and genetic modifiers ofthe progression to fibrosis and cirrhosis in hemochromatosis. Blood 2008;111:4456-62.
8. Weiss G. Genetic mechanisms and modifying factors in hereditary hemochromatosis. Nat Rev Gastroenterol Hepatol 2010;7:50-8.
9. Swinkels D Jorna A, Raymakers R. Synopsis of the Dutch multidisciplinary guideline for the diagnosis and treatment of hereditary haemochromatosis. Neth J Med 2007;65:452-5.
10. European Association for the Study of the Liver. EASL international consensus conference on haemochromatosis. J Hepatol 2000;33: 485-504.
11. Ellervik C, Birgens H, Tybjærg-Hansen A, Nordestgaard BG. Hemochromatosis genotypes and riskof 31 disease endpoints: meta-analyses including 66000 cases and 226000 controls. Hepatology 2007;46:1071-80. (Pubitemid 350144771)
12. Allen KJ, Bertalli NA, Osborne NJ, Constantine C, Delatycki MB, Nisselle AE, et al. HFE Cys282Tyr homozygotes with serum ferritin concentrations below 1000 μg/L are at low riskof hemochromatosis. Hepatology 2010;52:925-33.
13. McLaren GD, McLaren CE, Adams PC, Barton JC, Reboussin DM, Gordeuk VR, et al. Clinical manifestations of hemochromatosis in HFE C282Y homozygotes identified byscreening.Can J Gastroenterol 2008;22:923-30.
14. Pietrangelo A. The penetrance of hemochromatosis: mice to the rescue. Gastroenterology 2007;132:805-8.
15. Fischer R, Harmatz PR. Non-invasive assessment of tissue iron overload. Hematology 2009:215-21.
16. Swinkels DW Janssen MC, Bergmans J Marx JJ. Hereditary hemochromatosis: genetic complexity and new diagnostic approaches. Clin Chem 2006;52:950-68.
17. Kemna EH, Tjalsma H, Willems HL, Swinkels DW. Hepcidin: from discovery to differential diagnosis. Haematologica 2008;93:90-7.
18. McDonnell S, Phatak PS, Felitti V, Hover H, McLaren GD. Screening for hemochromatosis in primary care settings. Ann Intern Med 1998;129:962-70. (Pubitemid 28549834)
19. Bryant J, Cooper K, Picot J, Clegg A, Roderick P, Rosenberg W, et al. A systematic review ofthe clinical validity and clinical utility of DNA testing for hereditary haemochromatosis type 1 in at-risk populations. J Med Gen 2008;45:513-8.
20. Gurrin LC, Bertalli NA, Dalton GW, Osborne NJ, Constantine CC, McLaren CE, et al. HFE C282Y/H63D compound heterozygotes are at low risk of hemochromatosis-related morbidity. Hepatology 2009;50:94-101.
21. El-Serag HB, Inadomi JM, Kowdley KV. Screening for hereditary hemochromatosis in siblings and children of affected patients. A cost-effectiveness analysis. Ann Int Med 2000;132:261-9.
22. Asberg A, Hveem K, Thorstensen K, Ellekjter E, Kannelønning K, Fjøsne U, et al. Screening for hemochromatosis-high prevalence and low morbidity in an unselected population of 65 238 persons. Scand J Gastroenterol 2001;36:1108-15. (Pubitemid 32801699)
23. Niederau C, Fischer R, Sonnenberg A, Stremmel W, Trampisch HJ, Strohmeyer G, et al. Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis. N Engl J Med 1985;313:1256-62. (Pubitemid 16217048)
24. Elmberg M, Hultcrantz R, Ebrahim F,Olsson S, Lindgren S, Lööf L, et al. Increased mortality risk in patients with phenotypic hereditary hemochromatosis but not in their first-degree relatives. Gastroenterology 2009;137:1301-9.
25. Jacobs E, Hendriks J, Marx J, van Deursen C, Kreeftenberg H, de Vries R, et al. Morbidity and mortality in first-degree relatives of C282Y homozygous probands with clinically detected haemochromatosis compared with the general population: the HEmochromatosis FAmily Study (HEFAS).Neth J Med 2007;65:425-33.
26. Ellervik C, Mandrup-Poulsen T, Nordestgaard BG, Larsen EL, Appleyard M, Frandsen M, et al. Prevalence of hereditary haemochromatosis in late-onsettype 1 diabetes mellitus: a retrospective study. Lancet 2001;358:1405-9.
27. Niederau C, Fischer R, Pürschel A, Stremmel W, Häussinger D, Strohmeyer G. Long-term survival in patients with hereditary hemochromatosis. Gastroenterology 1996;110:1107-19. (Pubitemid 26113751)
28. US Preventive Services Task Force. Screening for hemochromatosis: recommendation statement. Ann Intern Med 2006;145:204-8.
29. Walsh A, Dixon JL, Ramm GA, Hewett DG, Lincoln DJ, Anderson GJ, et al. The clinical relevance of compound heterozygosity for the C282Y and H63D substitutions in hemochromatosis. Clin Gastroenterol Hepatol 2006;4:1403-10.
30. Jacobs EMG, Hendriks JCM, van Deursen CTBM, Kreeftenberg HG, de Vries RA, Marx JJM, et al. Severity of iron overload of proband determines serum ferritin levels in families with HFE-related hemochromatosis: The HEmochromatosis FAmily Study J Hepatol 2009;50:174-83.
31. Gurrin L, Osborne N, Constantine C, McLaren C, English D, Gertig D, et al. The natural history of serum iron indices for HFE C282Y homozygosity associated with hereditary hemochromatosis. Gastroenterology 2008;135:1945-52.
32. Seamark CJ, Hutchinson M, Heath I, McMullin MF. Controversy in primary care: Should asymptomatic haemochromatosis be treated? Treatment can be onerous for patient and doctor. BMJ 2000;320: 1314-7.
33. Van Dijk BA, Laarakkers CM, Klaver SM, Jacobs EM, van Tits LJH, Janssen MC, et al. Serum hepcidin levels are innately low in HFE-related haemochromatosis but differ between C282Y-homozygotes with elevated and normal ferritin levels. Br J Haematol 2008;142:979-85.
34. Hicken BL, Tucker DC, Barton JC. Patient compliance with phlebotomy therapy for iron overload associated with hemochromatosis. Am J Gastroenterol 2003;98:2072-7.
35. McDonnell S, Grindon A, Preston B, Barton J, Edwards C, Adams P. A survey of phlebotomy among persons with hemochromatosis. Transfus Apher Sci 1999;39:651-6.
36. Falize L, Guillygomarc'h A, Perrin M, Lainé F, Guyader D, Brissot P, et al. Reversibility of hepatic fibrosis in treated genetic hemochromatosis: a study of 36 cases. Hepatology 2006;44:472-7.
37. Rombout-Sestrienkova E, van Noord PA, van Deursen CT, Sybesma BJ, Nillesen-Meertens AE, Koek GH, et al. Therapeutic erythrocytapheresis versus phlebotomy in the initial treatment of hereditary hemochromatosis-a pilot study. Transfus Apher Sci 2007;36:261-7. (Pubitemid 47089103)
38. Beutler E. Iron storage disease: Facts, fiction and progress. Blood Cells Mol Dis 2007;39:140-7. (Pubitemid 47126927)
39. Morrison ED, Brandhagen DJ, PhatakPD, Barton JC, Krawitt EL, El-Serag HB, et al. Serum ferritin level predicts advanced hepatic fibrosis among US patients with phenotypic hemochromatosis. Ann Int Med 2003;138:627-33.